Pleural epithelioid mesothelioma

Summary

Pleural epithelioid mesothelioma (MONDO:0006378) is a disease and 4 clinical trials. Top therapeutic interventions include cisplatin. A subtype of malignant pleural mesothelioma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 4

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	pleural epithelioid mesothelioma
Mondo ID	MONDO:0006378
EFO	EFO:1000484
NCIT	C45662
UMLS	C1709574
MedGen	318031
GARD	0024387
Anatomy (UBERON)	UBERON:0000977
Is cancer (heuristic)	no

Also known as: malignant epithelioid mesothelioma of pleura · pleura malignant epithelioid mesothelioma · pleural epithelioid mesothelioma

Data availability: 105 cell lines.

Disease family

This is a subtype of malignant pleural mesothelioma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › mesothelial neoplasm › mesothelioma › pleural mesothelioma › malignant pleural mesothelioma › pleural epithelioid mesothelioma

Related subtypes (1): pleural sarcomatoid mesothelioma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 4.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE3	1
PHASE2	1
PHASE1/PHASE2	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04158141	PHASE3	TERMINATED	Testing the Addition of Targeted Radiation Therapy to Surgery and the Usual Chemotherapy Treatment (Pemetrexed and Cisplatin [or Carboplatin]) for Stage I-IIIA Malignant Pleural Mesothelioma
NCT07121374	PHASE1/PHASE2	RECRUITING	NEoadjuvant Chemotherapy and Immunotherapy for a Selected Group of Inoperable Pleural Mesothelioma Patients (NECIM): a Feasibility Study
NCT02399371	PHASE2	COMPLETED	Pembrolizumab in Treating Patients With Malignant Mesothelioma
NCT02672033	Not specified	TERMINATED	Accelerated Hypofractionated Radiation Therapy Immediately Before Surgery in Treating Patients With Malignant Pleural Mesothelioma

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CISPLATIN	4	1